ArticleFrontiers in oncology2020

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.

Francesca Urbani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.